QURE: uniQure N.V. Net earnings per share (EPS TTM)

The growth of uniQure N.V. (QURE) is based on the development of high-cost gene therapies with long-term patent protection. Fundamental earnings per share (TTM) as shown on the GURU.Markets chart confirms this trend, where the indicator value reaches -3.56. Leadership is driven by the world's first injections for hemophilia, while business resilience is guaranteed by Matt Kapusta's team and their own high-tech manufacturing facilities.
Metric breakdowns and analytics for uniQure N.V. (QURE)

This indicator serves as a capital stress-testing tool, allowing for an assessment of real equity returns without distortions from one-off quarterly reports. By analyzing the current EPS TTM level, an investor sees the net annual financial result per share, which for uniQure N.V. (QURE) reflects a period of intensive gene therapy expenditures that remain independent of market cycles.